Sponsored by
Early data from their phase 1 dose finding trial in recurrent Glioblastoma looks pretty good. This is a single injection of a targeted liposome that contains radiation. This targets the tumor theoretically without harming normal cells. We had a webinar about it last year https://virtualtrials.org/video2022.cfm?video=202205
This is now in clinical trials for adult recurrent glioblastoma, leptomeningeal spread as well as pediatric high grade gliomas and ependymomas. This is one of the very few trials that accept patients with leptomeningeal spread. They did not give numbers for the leptomeningeal group in this article but did say the treatment decreased the cell count in the cerebral spinal fluid.
Disclaimer: Plus Therapeutics is a sponsor of the Musella Foundation